CTOs on the Move

Marinus Pharmaceuticals

www.marinuspharma.com

 
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.marinuspharma.com
  • 5 Radnor Corporate Center 100 Matsonford Road Suite 500
    Radnor, PA USA 19087
  • Phone: 484.801.4670

Executives

Name Title Contact Details

Funding

Marinus Pharmaceuticals raised $70M on 12/13/2019

Similar Companies

Medsource RX

Medsource RX is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Silicon Therapeutics

Silicon Therapeutics is an integrated physics driven drug discovery company focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our platform closely represents the real dynamical nature of targets using accurate all-atom simulations, enabling us to design and optimize compounds for targets that were previously considered "undruggable." Our science, our team, and our mission are focused on applying advanced computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China

Trevi Therapeutics

Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.

ASP Global

We help you reach your savings targets and your patient experience goals by designing and delivering supplies and patient care products.

EIP Pharma

EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer’s disease.